Literature DB >> 16796588

Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity.

P E Vos1, M van Gils, T Beems, C Zimmerman, M M Verbeek.   

Abstract

Assessment of initial disease severity after subarachnoid haemorrhage (SAH) remains difficult. The objective of the study is to identify biochemical markers of brain damage in peripheral blood after SAH. Hospital admission S100beta, glial fibrillary acidic protein (GFAP) and neuron-specific enolase (NSE) serum levels were analysed in 67 patients with SAH. Disease severity was determined by using the World Federation of Neurological Surgeons (WFNS) scale and the Fisher CT (computerized tomography) grading scale. Mean astroglial serum concentrations taken at hospital admission were increased (S100beta 2.8-fold and GFAP 1.8-fold) compared with the upper limit of normal laboratory reference values (P95). The mean NSE concentration was within normal limits. S100beta (P < 0.001) and GFAP (P =0.011) but not NSE levels were higher in patients who were in coma at the time of hospital admission compared with patients who were not. Similarly S100beta and GFAP but not NSE serum levels increased with higher WFNS scores, raised intracranial pressure and higher CT Fisher grade scores. Concerning the location of the aneurysm, S100beta and GFAP serum levels were within normal limits after a perimesencephalic type of haemorrhage and significantly increased after aneurysmal type SAH. Increased glial (S100beta and GFAP) but not neuronal (NSE) protein serum concentrations are found after SAH, associated to the clinical severity of the initial injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796588     DOI: 10.1111/j.1468-1331.2006.01332.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  19 in total

Review 1.  A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury.

Authors:  Leora Schiff; Nandini Hadker; Silvia Weiser; Carsten Rausch
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.074

2.  Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas.

Authors:  Hatim Husain; William Savage; Stuart A Grossman; Xiaobu Ye; Peter C Burger; Allen Everett; Chetan Bettegowda; Luis A Diaz; Cherie Blair; Katharine E Romans; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2012-04-11       Impact factor: 4.130

3.  GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study.

Authors:  David O Okonkwo; John K Yue; Ava M Puccio; David M Panczykowski; Tomoo Inoue; Paul J McMahon; Marco D Sorani; Esther L Yuh; Hester F Lingsma; Andrew I R Maas; Alex B Valadka; Geoffrey T Manley
Journal:  J Neurotrauma       Date:  2013-08-01       Impact factor: 5.269

4.  A multiparameter panel method for outcome prediction following aneurysmal subarachnoid hemorrhage.

Authors:  Natacha Turck; Laszlo Vutskits; Paola Sanchez-Pena; Xavier Robin; Alexandre Hainard; Marianne Gex-Fabry; Catherine Fouda; Hadiji Bassem; Markus Mueller; Frédérique Lisacek; Louis Puybasset; Jean-Charles Sanchez
Journal:  Intensive Care Med       Date:  2009-09-17       Impact factor: 17.440

5.  Proteomics, bioinformatics and targeted gene expression analysis reveals up-regulation of cochlin and identifies other potential biomarkers in the mouse model for deafness in Usher syndrome type 1F.

Authors:  Mark R Chance; Jinsook Chang; Shuqing Liu; Giridharan Gokulrangan; Daniel H-C Chen; Aaron Lindsay; Ruishuang Geng; Qing Y Zheng; Kumar Alagramam
Journal:  Hum Mol Genet       Date:  2010-01-22       Impact factor: 6.150

6.  Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.

Authors:  Johan Undén; Karin Strandberg; Jan Malm; Eric Campbell; Lars Rosengren; Johan Stenflo; Bo Norrving; Bertil Romner; Arne Lindgren; Gunnar Andsberg
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

Review 7.  Biomarkers as outcome predictors in subarachnoid hemorrhage--a systematic review.

Authors:  Caron M Hong; Cigdem Tosun; David B Kurland; Volodymyr Gerzanich; David Schreibman; J Marc Simard
Journal:  Biomarkers       Date:  2014-02-05       Impact factor: 2.658

8.  S100 protein family and its application in clinical practice.

Authors:  F Sedaghat; A Notopoulos
Journal:  Hippokratia       Date:  2008       Impact factor: 0.471

Review 9.  Blood GFAP as an emerging biomarker in brain and spinal cord disorders.

Authors:  Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2022-02-03       Impact factor: 44.711

10.  Kallikrein 6 as a serum prognostic marker in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Eduardo Martínez-Morillo; Anastasia Diamandis; Alexander D Romaschin; Eleftherios P Diamandis
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.